The challenges of pharmacokinetic variability of first-line anti-TB drugs

References

• World Health Organization. Global tuberculosis report 2015. 2015 [cited 2016 Apr 29]. Available from: http://apps.who.int/iris/handle/10665/191102
   Google Scholar
• World Health Organization. Multi drug resistant tuberculosis. [updated 2015; cited 2016 Jul 21]. Available from: http://www.who.int/tb/challenges/mdr/mdr_tb_factsheet.pdf
   Google Scholar
• Chaulk CP, Moore-Rice K, Rizzo R, et al. Eleven years of community-based directly observed therapy for tuberculosis. JAMA. 1995;274:945–951.
   PubMed Web of Science ®Google Scholar
• Burhan E, Ruesen C, Ruslami R, et al. Isoniazid, rifampin, and pyrazinamide plasma concentrations in relation to treatment response in Indonesian pulmonary tuberculosis patients. Antimicrob Agents Chemother. 2013;57:3614–3619.
   PubMed Web of Science ®Google Scholar
• Kimerling ME, Phillips P, Patterson P, et al. Low serum antimycobacterial drug levels in non-HIV-infected tuberculosis patients. Chest. 1998;113:1178–1183.
   PubMed Web of Science ®Google Scholar
• Tappero JW, Bradford WZ, Agerton TB, et al. Serum concentrations of antimycobacterial drugs in patients with pulmonary tuberculosis in Botswana. Clin Infect Dis. 2005;41:461–469.
   PubMed Web of Science ®Google Scholar
• McIlleron H, Wash P, Burger A, et al. Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients. Antimicrob Agents Chemother. 2006;50:1170–1177.
   PubMed Web of Science ®Google Scholar
• Weiner M, Burman W, Vernon A, et al. Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine. Am J Respir Crit Care Med. 2003;167:1341–1347.
   PubMed Web of Science ®Google Scholar
• Weiner M, Benator D, Burman W, et al. Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. Clin Infect Dis. 2005;40:1481–1491.
   PubMed Web of Science ®Google Scholar
• Um SW, Lee SW, Kwon SY, et al. Low serum concentrations of anti-tuberculosis drugs and determinants of their serum levels. Int J Tuberc Lung Dis. 2007;11:972–978.
   PubMed Web of Science ®Google Scholar
• Mehta JB, Shantaveerapa H, Byrd RP, et al. Utility of rifampin blood levels in the treatment and follow-up of active pulmonary tuberculosis in patients who were slow to respond to routine directly observed therapy. Chest. 2001;120:1520–1524.
   PubMed Web of Science ®Google Scholar
• Pasipanodya JG, McIlleron H, Burger A, et al. Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J Infect Dis. 2013;208(9):1464–1473.
   PubMed Web of Science ®Google Scholar
• Reynolds J, Heysell SK. Understanding pharmacokinetics to improve tuberculosis treatment outcome. Expert Opin Drug Metab Toxicol. 2014;10:813–823.
   PubMed Web of Science ®Google Scholar
• D’Ambrosio L, Centis R, Sotgiu G, et al. New anti-tuberculosis drugs and regimens: 2015 update. ERJ Open Res. 2015;1:00010–2015.
   Google Scholar
• Srivastava S. Minimum inhibitory concentration, pharmacokinetics/pharmacodynamics and therapeutic drug monitoring: an integrated approach for multidrug-resistant tuberculosis. Lung India. 2015;32:402–403.
   PubMed Web of Science ®Google Scholar
• Srivastava S, Pasipanodya JG, Meek C, et al. Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability. J Infect Dis. 2011;204:1951–1959.
   PubMed Web of Science ®Google Scholar
• McIlleron H, Willemse M, Werely CJ, et al. Isoniazid plasma concentrations in a cohort of South African children with tuberculosis: implications for international pediatric dosing guidelines. Clin Infect Dis. 2009;48:1547–1553.
   PubMed Web of Science ®Google Scholar
• Ramachandran G, Hemanth Kumar AK, Bhavani PK, et al. Age, nutritional status and isoniazid acetylator status affect pharmacokinetics of anti-tuberculosis drugs in children. Int J Tuberc Lung Dis. 2013;17:800–806.
   PubMed Web of Science ®Google Scholar
• Walubo A, Chan K, Woo J, et al. The disposition of antituberculous drugs in plasma of elderly patients. II. Isoniazid, rifampicin and pyrazinamide. Methods Find Exp Clin Pharmacol. 1991;13:551–556.
   PubMedGoogle Scholar
• Requena-Méndez A, Davies G, Ardrey A, et al. Pharmacokinetics of rifampin in Peruvian tuberculosis patients with and without comorbid diabetes or HIV. Antimicrob Agents Chemother. 2012;56:2357–2363.
   PubMed Web of Science ®Google Scholar
• Fahimi F, Tabarsi P, Kobarfard F, et al. Isoniazid, rifampicin and pyrazinamide plasma concentrations 2 and 6 h post dose in patients with pulmonary tuberculosis. Int J Tuberc Lung Dis. 2013;17:1602–1606.
   PubMed Web of Science ®Google Scholar
• Hemanth Kumar AK, Kannan T, Chandrasekaran V, et al. Pharmacokinetics of thrice weekly rifampicin, isoniazid and pyrazinamide in adult tuberculosis patients in India. Int J Tuberc Lung Dis. 2016;20:1236–1241.
   PubMed Web of Science ®Google Scholar
• Graham SM, Bell DJ, Nyirongo S, et al. Low levels of pyrazinamide and ethambutol in children with tuberculosis and impact of age, nutritional status, and human immunodeficiency virus infection. Antimicrob Agents Chemother. 2006;50:407–413.
   PubMed Web of Science ®Google Scholar
• Hall RG, Swancutt MA, Meek C, et al. Ethambutol pharmacokinetic variability is linked to body mass in overweight, obese, and extremely obese people. Antimicrob Agents Chemother. 2012;56:1502–1507.
   PubMed Web of Science ®Google Scholar
• Ramachandran G, Kumar AKH, Kannan T, et al. Low serum concentrations of rifampicin and pyrazinamide associated with poor treatment outcomes in children with tuberculosis related to HIV status. Pediatr Infect Dis J. 2016;35:530–534.
   PubMed Web of Science ®Google Scholar
• Schaaf HS, Willemse M, Cilliers K, et al. Rifampin pharmacokinetics in children, with and without human immunodeficiency virus infection, hospitalized for the management of severe forms of tuberculosis. BMC Med. 2009;7:1.
   PubMed Web of Science ®Google Scholar
• Chideya S, Winston CA, Peloquin CA, et al. Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana. Clin Infect Dis. 2009;48:1685–1694.
   PubMed Web of Science ®Google Scholar
• Van Oosterhout JJ, Dzinjalamala FK, Dimba A, et al. Pharmacokinetics of antituberculosis drugs in HIV-positive and HIV-negative adults in Malawi. Antimicrob Agents Chemother. 2015;59:6175–6180.
   PubMed Web of Science ®Google Scholar
• Gurumurthy P, Ramachandran G, Hemanthkumar A, et al. Decreased bioavailability of rifampicin and other anti-TB drugs in patients with advanced HIV disease. Antimicrob Agents Chemother. 2004;48:4473–4475.
   PubMed Web of Science ®Google Scholar
• Hemanth Kumar AK, Ramachandran G, Rajasekaran S, et al. Pharmacokinetics of rifampicin during anti-retroviral treatment with non-nucleoside reverse transcriptase inhibitors. SAARC J Tuberc Lung Dis HIV/AIDS. 2008;V(2):1–4.
   Google Scholar
• López-Cortés LF, Ruiz-Valderas R, Viciana P, et al. Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis. Clin Pharmacokinet. 2002;41:681–690.
   PubMed Web of Science ®Google Scholar
• Bhatt NB, Barau C, Amin A, et al. Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine-or efavirenz-based antiretroviral treatment. Antimicrob Agents Chemother. 2014;58:3182–3190.
   PubMed Web of Science ®Google Scholar
• Peloquin CA, Namdar R, Singleton MD, et al. Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids. Chest. 1999;115:12–18.
   PubMed Web of Science ®Google Scholar
• Peloquin CA, Namdar R, Dodge AA, et al. Pharmacokinetics of isoniazid under fasting conditions, with food, and with antacids. Int J Tuberc Lung Dis. 1999;3:703–710.
   PubMed Web of Science ®Google Scholar
• Peloquin CA, Bulpitt AE, Jaresko GS, et al. Pharmacokinetics of pyrazinamide under fasting conditions, with food, and with antacids. Pharmacotherapy. 1998;18:1205–1211.
   PubMed Web of Science ®Google Scholar
• Polasa K, Krishnaswamy K. Effect of food on bioavailability of rifampicin. J Clin Pharmacol. 1983;23:433–437.
   PubMed Web of Science ®Google Scholar
• Peloquin CA, Bulpitt AE, Jaresko GS, et al. Pharmacokinetics of ethambutol under fasting conditions, with food, and with antacids. Antimicrob Agents Chemother. 1999;43:568–572.
   PubMed Web of Science ®Google Scholar
• Zent C, Smith P. Study on the effect of concomitant food on the bioavailability of rifampicin, isoniazid and pyrazinamide. Tuberc Lung Dis. 1995;76:109–113.
   PubMedGoogle Scholar
• Lin H-C, Yu M-C, Liu H-J, et al. Impact of food intake on the pharmacokinetics of first-line antituberculosis drugs in Taiwanese tuberculosis patients. J Formos Med Assoc. 2014;113:291–297.
   PubMed Web of Science ®Google Scholar
• Saktiawati Antonia MI, Sturkenboom MGG, Stienstra Y, et al. Impact of food on the pharmacokinetics of first-line anti-TB drugs in treatment-naive TB patients: a randomized cross-over trial. J Antimicrob Chemother. 2016;71:703–710.
   PubMed Web of Science ®Google Scholar
• Hemath Kumar AK, Chandrasekaran V, Kumar K, et al. Food significantly reduces plasma concentrations of first-line anti-TB drugs. Indian J Med Res. Forthcoming 2016.
   Google Scholar
• Babalik A, Ulus IH, Bakirci N, et al. Plasma concentrations of isoniazid and rifampin are decreased in adult pulmonary tuberculosis patients with diabetes mellitus. Antimicrob Agents Chemother. 2013;57:5740–5742.
   PubMed Web of Science ®Google Scholar
• Nijland HMJ, Ruslami R, Stalenhoef JE, et al. Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes. Clin Infect Dis. 2006;43:848–854.
   PubMed Web of Science ®Google Scholar
• Cascorbi I, Roots I. Pitfalls in N-acetyl transferase 2 genotyping. Pharmacogenetics. 1999;9(1):123–127.
   PubMedGoogle Scholar
• Kinzig-Schippers M, Tomalik-Scharte D, Jetter A, et al. Should we use N-acetyl transferase type 2 genotyping to personalize isoniazid doses? Antimicrob Agents Chemother. 2005;49(5):1733–1738.
   PubMed Web of Science ®Google Scholar
• Parkin DP, Vandenplas S, Botha FJ, et al. Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosis. Am J Respir Crit Care Med. 1997;155(5):1717–1722.
   PubMed Web of Science ®Google Scholar
• Kita T, Tanigawara Y, Chikazawa S, et al. N-acetyl transferase-2 genotype correlated with isoniazid acetylation in Japanese tuberculous patients. Biol Pharm Bull. 2001;24(5):544–549.
   PubMed Web of Science ®Google Scholar
• Wang P-Y, Xie S-Y, Hao Q, et al. NAT2 polymorphisms and susceptibility to anti-tuberculosis drug-induced liver injury: a meta-analysis. Int J Tuberc Lung Dis. 2012;16:589–595.
   PubMed Web of Science ®Google Scholar
• Ji B, Truffot Pernot C, Lacroix C, et al. Effectiveness of rifampin, rifabutin and rifapentine for preventive therapy of tuberculosis in mice. Am Rev Respir Dis. 1993;148:1541–1546.
   PubMed Web of Science ®Google Scholar
• Weiner M, Peloquin CA, Burman W, et al. Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations. Antimicrob Agents Chemother. 2010;54(10):4192–4200.
   PubMed Web of Science ®Google Scholar
• Chigutsa E, Visser ME, Swart EC, et al. The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: dosing implications. Antimicrob Agents Chemother. 2011;55(9):4122–4127.
   PubMed Web of Science ®Google Scholar
• Lin JH. Pharmacokinetic and pharmacodynamic variability: a daunting challenge in drug therapy. Curr Drug Metab. 2007;8:109–136.
   PubMed Web of Science ®Google Scholar
• Alsultan A, Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis: an update. Drugs. 2014;74:839–854.
   PubMed Web of Science ®Google Scholar
• Pasipanodya JG, Srivastava S, Gumbo T. Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy. Clin Infect Dis. 2012;55(2):169–177.
   PubMed Web of Science ®Google Scholar
• Pasipanodya JG, Gumbo T. A new evolutionary and pharmacokinetic–pharmacodynamic scenario for rapid emergence of resistance to single and multiple anti-tuberculosis drugs. Curr Opin Pharmacol. 2011;11:457–463.
   PubMed Web of Science ®Google Scholar
• Ramachandran G, Kumar AKH, Swaminathan S. Pharmacokinetics of anti-tuberculosis drugs in children. Indian J Pediatr. 2011;78:435–442.
   PubMed Web of Science ®Google Scholar
• Wilkins JJ, Langdon G, McIlleron H, et al. Variability in the population pharmacokinetics of pyrazinamide in South African tuberculosis patients. Eur J Clin Pharmacol. 2006;62:727–735.
   PubMed Web of Science ®Google Scholar
• Wilkins JJ, Langdon G, McIlleron H, et al. Variability in the population pharmacokinetics of isoniazid in South African tuberculosis patients. Br J Clin Pharmacol. 2011;72:51–62.
   PubMed Web of Science ®Google Scholar
• Milán Segovia RC, Domínguez Ramírez AM, Jung Cook H, et al. Population pharmacokinetics of rifampicin in Mexican patients with tuberculosis. J Clin Pharm Ther. 2013;38:56–61.
   PubMed Web of Science ®Google Scholar
• Zhu M, Starke JR, Burman WJ, et al. Population pharmacokinetic modeling of pyrazinamide in children and adults with tuberculosis. Pharmacotherapy. 2002;22:686–695.
   PubMed Web of Science ®Google Scholar
• King JR, Kimberlin DW, Aldrovandi GM, et al. Antiretroviral pharmacokinetics in the paediatric population. Clin Pharmacokinet. 2002;41:1115–1133.
   PubMed Web of Science ®Google Scholar
• Kearns GL, Abdel-Rahman SM, Alander SW, et al. Developmental pharmacology – drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349:1157–1167.
   PubMed Web of Science ®Google Scholar
• Thee S, Detjen AA, Wahn U, et al. Isoniazid pharmacokinetic studies of the 1960s: considering a higher isoniazid dose in childhood tuberculosis. Scand J Infect Dis. 2010;42:294–298.
   PubMed Web of Science ®Google Scholar
• Mukherjee A, Velpandian T, Singla M, et al. Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in Indian children. BMC Infect Dis. 2015;15:126.
   PubMed Web of Science ®Google Scholar
• Mlotha R, Waterhouse D, Dzinjalamala F, et al. Pharmacokinetics of anti-TB drugs in Malawian children: reconsidering the role of ethambutol. J Antimicrob Chemother. 2015;70:1798–1803.
   PubMed Web of Science ®Google Scholar
• Thee S, Seddon JA, Donald PR, et al. Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations. Antimicrob Agents Chemother. 2011;55:5560–5567.
   PubMed Web of Science ®Google Scholar
• Le Doare K, Barber N, Doerholt K, et al. Rifampicin pharmacokinetics in extreme prematurity to treat congenital tuberculosis. Case Reports. 2013;2013:bcr2012008207. DOI:10.1136/bcr-2012-008207
   PubMedGoogle Scholar
• Pullen J, Stolk LML, Degraeuwe PLJ, et al. Pharmacokinetics of intravenous rifampicin (rifampin) in neonates. Ther Drug Monit. 2006;28:654–661.
   PubMed Web of Science ®Google Scholar
• Advenier C, Gobert C, Houin G, et al. Pharmacokinetic studies of rifampicin in the elderly. Ther Drug Monit. 1983;5:61–66.
   PubMed Web of Science ®Google Scholar
• Keung ACF, Eller MG, Weir SJ. Single-dose pharmacokinetics of rifapentine in elderly men. Pharm Res. 1998;15:1286–1291.
   PubMed Web of Science ®Google Scholar
• Krishnaswamy K. Drug metabolism and pharmacokinetics in malnourished children. Clin Pharmacokinet. 1989;17:68–88.
   PubMed Web of Science ®Google Scholar
• Mehta S. Malnutrition and drugs: clinical implications. Dev Pharmacol Ther. 1989;15:159–165.
   Google Scholar
• Vijayakumar M, Bhaskaram P, Hemalatha P. Malnutrition and childhood tuberculosis. J Trop Pediatr. 1990;36:294–298.
   PubMed Web of Science ®Google Scholar
• Ruslami R, Nijland HM, Alisjahbana B, et al. Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients. Antimicrob Agents Chemother. 2007;51:2546–2551.
   PubMed Web of Science ®Google Scholar
• Hall RG. Evolving larger: dosing anti-tuberculosis (TB) drugs in an obese world. Curr Pharm Des. 2015;21:4748–4751.
   PubMed Web of Science ®Google Scholar
• McIlleron H, Rustomjee R, Vahedi M, et al. Reduced antituberculosis drug concentrations in HIV-infected patients who are men or have low weight: implications for international dosing guidelines. Antimicrob Agents Chemother. 2012;56:3232–3238.
   PubMed Web of Science ®Google Scholar
• Eriksson M, Bolme P, Habte D, et al. INH and streptomycin in Ethiopian children with tuberculosis and different nutritional status. Acta Paediatr. 1988;77:890–894.
   PubMed Web of Science ®Google Scholar
• Seifart HI, Donald PR, De Villiers JN, et al. Isoniazid elimination kinetics in children with protein-energy malnutrition treated for tuberculous meningitis with a four-component antimicrobial regimen. Ann Trop Paediatr. 1995;15:249–254.
   PubMed Web of Science ®Google Scholar
• McIlleron H, Willemse M, Schaaf HS, et al. Pyrazinamide plasma concentrations in young children with tuberculosis. Pediatr Infect Dis J. 2011;30:262–265.
   PubMed Web of Science ®Google Scholar
• Havlir DV, Barnes PF. Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med. 1999;340:367–373.
   PubMed Web of Science ®Google Scholar
• Swaminathan S, Deivanayagam CN, Rajasekaran S, et al. Long term follow up of HIV-infected patients with tuberculosis treated with 6-month intermittent short course chemotherapy. Natl Med J India. 2008;21:3.
   PubMed Web of Science ®Google Scholar
• Khan FA, Minion J, Pai M, et al. Treatment of active tuberculosis in HIV-coinfected patients: a systematic review and meta-analysis. Clin Infect Dis. 2010;50:1288–1299.
   PubMed Web of Science ®Google Scholar
• Jeena P, Pillay P, Pillay T, et al. Impact of HIV-1 co-infection on presentation and hospital-related mortality in children with culture proven pulmonary tuberculosis in Durban, South Africa. Int J Tuberc Lung Dis. 2002;6:672–678.
   PubMed Web of Science ®Google Scholar
• Rekha B, Swaminathan S. Childhood tuberculosis – global epidemiology and the impact of HIV. Paediatr Respir Rev. 2007;8:99–106.
   PubMed Web of Science ®Google Scholar
• Ramachandran G, Kumar AKH, Bhavani PK, et al. Pharmacokinetics of first-line antituberculosis drugs in HIV-infected children with tuberculosis treated with intermittent regimens in India. Antimicrob Agents Chemother. 2015;59:1162–1167.
   PubMed Web of Science ®Google Scholar
• Mukherjee A, Velpandian T, Singla M, et al. Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in HIV-infected Indian children. Int J Tuberc Lung Dis. 2016;20:666–672.
   PubMed Web of Science ®Google Scholar
• Niazi AK, Kalra S. Diabetes and tuberculosis: a review of the role of optimal glycemic control. J Diabetes Metab Disord. 2012;11:1.
   PubMedGoogle Scholar
• Jeon CY, Harries AD, Baker MA, et al. Bi-directional screening for tuberculosis and diabetes: a systematic review. Trop Med Int Health. 2010;15:1300–1314.
   PubMed Web of Science ®Google Scholar
• Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med. 2003;167:603–662.
   PubMed Web of Science ®Google Scholar
• Ruslami R, Nijland HM, Adhiarta IGN, et al. Pharmacokinetics of antituberculosis drugs in pulmonary tuberculosis patients with type 2 diabetes. Antimicrob Agents Chemother. 2010;54:1068–1074.
   PubMed Web of Science ®Google Scholar
• Matsuki Y, Katakuse Y, Matsuura H, et al. Effects of glucose and ascorbic acid on absorption and first pass metabolism of isoniazid in rats. Chem Pharm Bull (Tokyo). 1991;39:445–448.
   PubMed Web of Science ®Google Scholar
• Chang MJ, Chae J, Yun H, et al. Effects of type 2 diabetes mellitus on the population pharmacokinetics of rifampin in tuberculosis patients. Tuberculosis. 2015;95:54–59.
   PubMed Web of Science ®Google Scholar
• Melander A. Influence of food on the bioavailability of drugs. Clin Pharmacokinet. 1978;3:337–351.
   PubMed Web of Science ®Google Scholar
• Lin MY, Lin SJ, Chan LC, et al. Impact of food and antacids on the pharmacokinetics of anti-tuberculosis drugs: systematic review and meta-analysis. Int J Tuberc Lung Dis. 2010;14:806–818.
   PubMed Web of Science ®Google Scholar
• Panchagnula R, Rungta S, Sancheti P, et al. In vitro evaluation of food effect on the bioavailability of rifampicin from antituberculosis fixed dose combination formulations. Farm Soc Chim Ital 1989. 2003;58:1099–1103.
   Google Scholar
• Pillai G, Fourie PB, Padayatchi N, et al. Recent bioequivalence studies on fixed-dose combination anti-tuberculosis drug formulations available on the global market. Int J Tuberc Lung Dis. 1999;3(Suppl 3):S309–S316.
   PubMed Web of Science ®Google Scholar
• Karczewski KJ, Daneshjou R, Altman RB. Chapter 7: pharmacogenomics. PLoS Comput Biol. 2012;8:e1002817.
   PubMed Web of Science ®Google Scholar
• Ramachandran G, Swaminathan S. Role of pharmacogenomics in the treatment of tuberculosis: a review. Pharmgenomics Pers Med. 2012;5:89–98.
   PubMedGoogle Scholar
• Verhagen LM, Coenen M, López D, et al. Full-gene sequencing analysis of NAT2 and its relationship with isoniazid pharmacokinetics in Venezuelan children with tuberculosis. Pharmacogenomics. 2014;15:285–296.
   PubMed Web of Science ®Google Scholar
• Devadatta S, Gangadharam PRJ, Andrews RH, et al. Peripheral neuritis due to isoniazid. Bull WHO. 1960;23:587–598.
   PubMedGoogle Scholar
• Tuberculosis Chemotherapy Centre, Madras. The prevention and treatment of isoniazid toxicity in the therapy of pulmonary tuberculosis 2. An assessment of the prophylactic effect of pyridoxine in low dosage. Bull WHO. 1963;29:457–481.
   PubMed Web of Science ®Google Scholar
• Roy PD, Majumder M, Roy B. Pharmacogenomics of anti-TB drug-related hepatotoxicity. Pharmacogenomics. 2008;9(3):311–321.
   PubMed Web of Science ®Google Scholar
• Lee S-W, Chung L, Huang -H-H, et al. NAT2 and CYP2E1 polymorphisms and susceptibility to first-line anti-tuberculosis drug-induced hepatitis. Int J Tuberc Lung Dis. 2010;14:622–626.
   PubMed Web of Science ®Google Scholar
• Cho H-J, Koh W-J, Ryu Y-J, et al. Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis. Tuberculosis. 2007;87:551–556.
   PubMed Web of Science ®Google Scholar
• Stettner M, Steinberger D, Hartmann CJ, et al. Isoniazid-induced polyneuropathy in a tuberculosis patient – implication for individual risk stratification with genotyping? Brain Behav. 2015;5:e00326.
   PubMed Web of Science ®Google Scholar
• Azuma J, Ohno M, Kubota R, et al. NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy. Eur J Clin Pharmacol. 2013;69:1091–1101.
   PubMed Web of Science ®Google Scholar
• Kubota R, Ohno M, Hasunuma T, et al. Dose-escalation study of isoniazid in healthy volunteers with the rapid acetylator genotype of arylamine N-acetyl transferase 2. Eur J Clin Pharmacol. 2007;63:927–933.
   PubMed Web of Science ®Google Scholar
• Hemanth Kumar AK, Ramesh K, Kannan T, et al. NAT2 gene polymorphisms and plasma isoniazid concentrations in tuberculosis patients in south India. Indian J Med Res. Forthcoming 2016.
   Google Scholar
• Grosset JH, Rosenthal IM, Zhang M, et al. Dose ranging comparison of rifampin and rifapentine in combination with isoniazid and pyrazinamide in the mouse model of tuberculosis. Abstract A-1825, 48th Annual Interscience Conference of Antimicrobial Agents Chemotherapy (ICAAC), Infectious Diseases Society of America (IDSA) 46th Annual Meeting of American Society for Microbiology and Infectious Diseases Society of America; 2008; Oct 27, Washington, DC.
   Google Scholar
• Jayaram R, Gaonkar S, Kaur P, et al. Pharmacokinetics and pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother. 2003;47(7):2118–2124.
   PubMed Web of Science ®Google Scholar
• Jeremiah K, Denti P, Chigutsa E, et al. Nutritional supplementation increases rifampin exposure among tuberculosis patients co-infected with HIV. Antimicrob Agents Chemother. 2014;58:3468–3474.
   PubMed Web of Science ®Google Scholar
• He Y-J, Zhang W, Chen Y, et al. Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism. Clin Chim Acta. 2009;405:49–52.
   PubMed Web of Science ®Google Scholar
• Ramesh K, Hemanth Kumar AK, Kannan T, et al. SLCO1B1 gene polymorphisms do not influence plasma rifampicin concentrations in a south Indian population. Int J Tuberc Lung Dis. 2016;20:1231–1235.
   PubMed Web of Science ®Google Scholar
• Laseron KF, Kenyon AS, Kenyon TA, et al. Substandard tuberculosis drugs on the global market and their simple detection. Int J Tuber Lung Dis. 2001;5:448–454.
   PubMed Web of Science ®Google Scholar
• Panchagnula R, Agrawal S. Biopharmaceutic and pharmacokinetic aspects of variable bioavailability of rifampicin. Int J Pharm. 2004;271:1–4.
   PubMed Web of Science ®Google Scholar
• Heysell SK, Moore J, Keller SJ, et al. Therapeutic drug monitoring for slow response to tuberculosis treatment in a state control program, Virginia, USA. Emerg Infect Dis. 2010;16(10):1546–1553.
   PubMed Web of Science ®Google Scholar
• Babalik A, Mannix S, Francis D, et al. Therapeutic drug monitoring in the treatment of active tuberculosis. Can Respir J. 2011;18(4):225–229.
   PubMed Web of Science ®Google Scholar
• Van Tongeren L, Nolan S, Cook VJ, et al. Therapeutic drug monitoring in the treatment of tuberculosis: a retrospective analysis. Int J Tuberc Lung Dis. 2013;17(2):221–224.
   PubMed Web of Science ®Google Scholar
• Ray J, Gardiner I, Marriott D. Managing antituberculosis drug therapy by therapeutic drug monitoring of rifampicin and isoniazid. Intern Med J. 2003;33(5–6):229–234.
   PubMed Web of Science ®Google Scholar
• Heysell SK, Moore JL, Staley D, et al. Early therapeutic drug monitoring for isoniazid and rifampin among diabetics with newly diagnosed tuberculosis in Virginia, USA. Tuberc Res Treat. 2013;2013: Article ID 129723, 6 pages. doi:10.1155/2013/129723
   PubMedGoogle Scholar
• Lin JH, Lu AY. Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet. 1998;35(5):361–390.
   PubMed Web of Science ®Google Scholar
• Sousa M, Pozniak A, Boffito M. Pharmacokinetics and pharmacodynamics of drug interactions involving rifampicin, rifabutin and antimalarial drugs. J Antimicrob Chemother. 2008;62(5):872–878.
   PubMed Web of Science ®Google Scholar
• Yew WW. Clinically significant interactions with drugs used in the treatment of tuberculosis. Drug Saf. 2002;25:111–113.
   PubMed Web of Science ®Google Scholar
• Niemi M, Backman JT, Fromm MF, et al. Pharmacokinetic interactions with rifampicin. Clin Pharmacokinet. 2003;42(9):819–850.
   PubMed Web of Science ®Google Scholar
• Zilly W, Breimer DD, Richter E. Pharmacokinetic interactions with rifampicin. Clin Pharmacokinet. 1977;2(1):61–70.
   PubMed Web of Science ®Google Scholar
• Desta Z, Soukhova NV, Flockhart DA. Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: potent inhibition of CYP2C19 and CYP3A. Antimicrob Agents Chemother. 2001;45(2):382–392.
   PubMed Web of Science ®Google Scholar
• Michalets EL. Update: clinically significant cytochrome P‐450 drug interactions. Pharmacother J Human Pharmacol Drug Ther. 1998;18(1):84–112.
   Google Scholar
• Baciewicz AM, Self TH. Isoniazid interactions. Southern Med J. 1985;78(6):714–718.
   PubMed Web of Science ®Google Scholar
• Arbex MA, Varella MD, Siqueira HR, et al. Antituberculosis drugs: drug interactions, adverse effects, and use in special situations-part 1: first-line drugs. J Brasileiro De Pneumologia. 2010;36(5):626–640.
   PubMed Web of Science ®Google Scholar
• Weber WW, Hein DW. Clinical pharmacokinetics of isoniazid. Clin Pharmacokinet. 1979;4(6):401–422.
   PubMed Web of Science ®Google Scholar
• Kwara A, Flanigan TP, Carter EJ. Highly active antiretroviral therapy (HAART) in adults with tuberculosis: current status. Int J Tuberc Lung Dis. 2005;9(3):248–257.
   PubMed Web of Science ®Google Scholar
• Maartens G, Decloedt E, Cohen K. Effectiveness and safety of antiretrovirals with rifampicin: crucial issues for high-burden countries. Antivir Ther. 2009;14(8):1039–1043.
   PubMed Web of Science ®Google Scholar
• Friedland G, Khoo S, Jack C, et al. Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV. J Antimicrob Chemother. 2006;58(6):1299–1302.
   PubMed Web of Science ®Google Scholar
• Semvua HH, Kibiki GS, Kisanga ER, et al. Pharmacological interactions between rifampicin and antiretroviral drugs: challenges and research priorities for resource-limited settings. Ther Drug Monit. 2015;37(1):22–32.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Managing drug interactions in the treatment of HIV-related tuberculosis. 2007 [cited 2016 Oct 1]. Available from: http://www.cdc.gov/tb/publications/guidelines/tb_hiv_drugs/recommendations02.htm
   Google Scholar
• Wenning LA, Hanley WD, Brainard DM, et al. Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir. Antimicrob Agents Chemother. 2009;53(7):2852–2856.
   PubMed Web of Science ®Google Scholar